Yunu CEO Advocates for Enhanced Imaging Workflow in Clinical Trials for Better Outcomes

During the LSI Emerging Medtech Summit in Dana Point, CA, Yunu CEO Jeff Sorenson called attention to the critical role of imaging in the efficiency and effectiveness of clinical trials. Sorenson exposed the challenges plaguing clinical trial imaging, including high error rates in image assessment and inefficiencies that impact patient enrollment and treatment. Yunu's cloud platform aims to address these issues by enhancing connectivity among all stakeholders and ensuring precise data management.

Sorenson emphasized the potential of AI in drug development, contingent upon the availability of accurate and comprehensive data, including imaging. Yunu, with a team specialized in medical imaging and life sciences, is pioneering this effort by managing over 4,200 active clinical trials. The company's recent partnerships with a prestigious cancer center, a professional medical society imaging core lab, and a leading children's research hospital underscore its commitment to rewriting the norms of clinical trial imaging workflows.

Yunu's innovative approach promises to streamline imaging workflows, minimize errors, and expedite the drug development process. As real-time data access and intelligent workflow optimizations become increasingly vital, Yunu is poised to lead the charge in transforming clinical trial imaging for better, faster outcomes.